Valuation: Amgen Inc.

Market Cap 196B 172B 158B 146B 277B 18,705B 282B 1,891B 742B 9,215B 736B 720B 31,678B P/E 2026 *
23.8x
P/E 2027 * 21.8x
Enterprise Value 238B 208B 192B 178B 337B 22,720B 342B 2,296B 902B 11,193B 894B 875B 38,478B EV / Sales 2026 *
6.31x
EV / Sales 2027 * 6.01x
Free-Float
99.78%
Yield 2026 *
2.78%
Yield 2027 * 2.93%
1 day+0.25%
1 week-2.54%
Current month+1.30%
1 month+4.96%
3 months+6.09%
6 months+12.64%
Current year+13.65%
1 week 316
Extreme 316
327.65
1 month 291.7
Extreme 291.7
327.65
Current year 271.8
Extreme 271.8
333
1 year 230
Extreme 230
333
3 years 200.8
Extreme 200.8
333
5 years 174.58
Extreme 174.58
333
10 years 120.65
Extreme 120.65
333
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Director of Finance/CFO 67 31/12/2019
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-2.54% - - 196B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-3.72%-1.10%+18.41%+70.56% 161B
-0.33%-0.62%-5.77%-32.90% 138B
Average -1.06%-2.99%+23.52%+46.12% 390.62B
Weighted average by Cap. -1.26%-2.87%+35.85%+80.53%

Financials

2026 *2027 *
Net sales 37.76B 33.03B 30.47B 28.14B 53.39B 3,602B 54.29B 364B 143B 1,774B 142B 139B 6,100B 38.69B 33.84B 31.22B 28.83B 54.7B 3,690B 55.62B 373B 146B 1,818B 145B 142B 6,249B
Net income 8.23B 7.2B 6.64B 6.13B 11.64B 785B 11.83B 79.34B 31.16B 387B 30.9B 30.23B 1,329B 8.86B 7.75B 7.15B 6.6B 12.53B 845B 12.74B 85.4B 33.54B 416B 33.26B 32.54B 1,431B
Net Debt 42.1B 36.82B 33.96B 31.37B 59.52B 4,015B 60.52B 406B 159B 1,978B 158B 155B 6,800B 36.55B 31.97B 29.49B 27.24B 51.68B 3,486B 52.55B 352B 138B 1,717B 137B 134B 5,904B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
10/07/26 €318.55 +0.25% 92
09/07/26 €317.75 -1.61% 283
08/07/26 €322.95 +0.19% 711
07/07/26 €322.35 +1.32% 209
06/07/26 €318.15 -2.66% 295
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
363.39USD
Average target price
355.76USD
Spread / Average Target
-2.10%

Quarterly revenue - Rate of surprise